Single Dose Gonadotropin-releasing Hormone (GnRH) Agonist Administration in the Luteal Phase of GnRH Antagonist Stimulated ICSI-ET Cycles
Overview
- Phase
- Phase 3
- Intervention
- NaCl %0.9
- Conditions
- Infertility
- Sponsor
- V.K.V. American Hospital, Istanbul
- Locations
- 1
- Primary Endpoint
- Ongoing pregnancy beyond 20th gestational week
- Status
- Terminated
- Last Updated
- 16 years ago
Overview
Brief Summary
GnRH agonist administration in the luteal phase was reported to beneficially affect clinical outcome of ICSI-ET cycles. This randomized controlled trial evaluates the effect of a single dose GnRH agonist administered in the luteal phase on the outcome of ICSI - ET cycles stimulated with the fixed GnRH antagonist protocol. Women undergoing embryo transfer following controlled ovarian hyperstimulation with a fixed GnRH antagonist protocol were included. In addition to routine luteal phase support with progesterone women were randomized to receive a single dose of GnRH agonist or placebo on the sixth day after ICSI.Ongoing pregnancy rate was the primary outcome measure.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Women undergoing embryo transfer following controlled ovarian hyperstimulation with a fixed GnRH antagonist protocol, oocyte pick-up and ICSI.
- •Embryo transfer performed on day 3
Exclusion Criteria
- •Participation in another trial that was being conducted in our unit at the same time.
- •Preimplantation genetic screening cycles.
- •Day 5 embryo transfers.
Arms & Interventions
Saline
Intervention: NaCl %0.9
GnRH agonist
Intervention: triptorelin acetate
Outcomes
Primary Outcomes
Ongoing pregnancy beyond 20th gestational week
Secondary Outcomes
- clinical pregnancy rate
- Embryo implantation rate